MLYS — Mineralys Therapeutics, Inc. stock price, charts and financials

QT50Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
28.02
+0.04+0.14%
OverviewShort InterestFilings
MLYSQT50Mineralys Therapeutics, Inc.·NASDAQ
28.02+0.14%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
VERA-0.79%$34.00VRDN+0.32%$22.00HRMY-1.68%$42.02PHVS-4.29%$36.37CLDX-1.90%$38.24BEAM+1.14%$24.95NAMS+2.55%$22.49NRIX-0.24%$25.44
Snapshot
Index-P/E-EPS (ttm)-Insider Own36.10%Shs Outstand88.16MPerf Week-0.64%
Market Cap2.47BForward P/E-EPS next Y-2.43Insider Trans-0.09%Shs Float61.91MPerf Month3.97%
Enterprise Value1.91BPEG-EPS next Q-0.53Inst Own-Short Float15.07%Perf Quarter13.76%
Income-155.00MP/S0.00EPS this Y-Inst Trans-Short Ratio7.17Perf Half Y20.36%
Sales0.00P/B4.48EPS next Y45.87%ROA-52.34%Short Interest9.33MPerf YTD-22.79%
Book/sh6.25P/C3.74EPS next 5Y-ROE-57.97%52W High47.65 -41.20%Perf Year-24.86%
Cash/sh7.50P/FCF-EPS past 3/5Y-ROIC-57.17%52W Low22.30 25.65%Perf 3Y133.11%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.12% 5.29%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-15.85%Oper. Margin0.00%ATR (14)1.49Perf 10Y-
Dividend Ex-Date-Quick Ratio34.46Sales Y/Y TTM-Profit Margin0.00%RSI (14)51.67Recom2.13
Dividend Gr. 3/5Y-Current Ratio34.46EPS Q/Q-331.82%SMA201.51%Beta1.15Target Price43.20
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA503.30%Rel Volume3.43Prev Close27.98
Employees76LT Debt/Eq0.18EarningsNov 09SMA200-3.39%Avg Volume1.10MPrice28.02
IPO DateFeb 10, 2023Option/ShortYes / YesEPS/Sales Surpr.-419.53% -Net Debt/EBITDA0.12Volume3,786,935Change0.14%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-13-26ReiteratedJefferiesHold$30
Mar-10-26ReiteratedH.C. WainwrightBuy$52 → $56
Dec-19-25ReiteratedStifel Nicolaus$45 → $52
Oct-30-25ReiteratedHC Wainwright & Co.Buy$42 → $52
May-14-25ReiteratedGuggenheimBuy$52 → $48
Apr-02-25ReiteratedHC Wainwright & Co.Buy$42
Apr-02-24ReiteratedGoldman Sachs$30
Latest News· Times ET
Sep-09-26
Sep-09-2612:05PM
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Sep-07-26
Sep-07-2612:18AM
Greenland Capital Management LP Sells 53,500 Shares of Mineralys Therapeutics, Inc. $MLYSdefenseworld.net
Sep-03-26
Sep-03-2612:25PM
Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decisionseekingalpha.com
Sep-01-26
Sep-01-2612:03AM
Canada Pension Plan Investment Board Buys New Holdings in Mineralys Therapeutics, Inc. $MLYSdefenseworld.net
Aug-29-26
Aug-29-2612:00AM
BlackRock Inc. Buys New Position in Mineralys Therapeutics, Inc. $MLYSdefenseworld.net
Aug-27-26
Aug-27-2603:09PM
THQ Offers High-Yield Income From Healthcare Stocks (Rating Upgrade)SeekingAlpha
Aug-26-26
Aug-26-2604:00AM
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conferenceglobenewswire.com
Aug-13-26
Aug-13-2612:05PM
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Aug-11-26
Aug-11-2609:17PM
Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcriptseekingalpha.com
03:05PM
Mineralys Therapeutics Q2 Earnings Call Highlightsmarketbeat.com
12:05PM
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com
Jul-27-26
Jul-27-2612:01PM
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Jul-03-26
Jul-03-2609:41AM
A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A MultibaggerYahoo
Jun-17-26
Jun-17-2606:58PM
Mineralys: Limited Differentiation Makes Lorundrostat A Weak CompetitorSeekingAlpha
09:35AM
7 Health Care Stocks With Whale Alerts In Today's SessionBenzinga
Company

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue
000———
Cost of Goods Sold Incl. D&A
000———
Gross Profit
000———
Selling, General and Administrative Excl. Other392414———
Research and Development13216970———
Other Operating Expense0-11———
Operating Income-171-192-85———
Interest Expense
000———
Unusual Expense
——————
Non-Operating Income (Expense)161513———
Net Income Before Taxes-155-178-72———
Income Taxes
000———
Consolidated Net Income-155-178-72———
Net Income From Continuing Operations-155-178-72———
Net Income-155-178-72———
EPS (Recurring)-2.29-3.66-1.99———
EPS (Basic, Before Extraordinaries)-2.29-3.66-1.99———
EPS (Diluted)-2.29-3.66-1.99———
EBITDA-155-178-72———
Other After Tax Adjustments
——————
Stock Option Compensation Expense
——————
Price To Earnings Ratio
——————
Price To Sales Ratio
——————
Gross Margin
——————
Operating Margin
——————
Net Margin
——————
Shares Outstanding684936———
Market Capitalization2,468603310———
Operating Lease Expense
——————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$52.50$41.30$30.10$18.90$7.70● Close Price0.00M15.02M30.03M45.05M60.07MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Karydas DaphneDirectorSep 15 '26Sale28.583,00085,7406,200Sep 17
Karydas DaphneDirectorSep 15 '26Option Exercise12.023,00036,0609,200Sep 17
Warren EricChief Commercial OfficerAug 21 '26Option Exercise13.247,43798,46645,837Aug 25
Warren EricChief Commercial OfficerAug 21 '26Sale25.987,437193,18938,400Aug 25
Rodman David MalcomChief Medical OfficerAug 10 '26Option Exercise16.002,17034,72053,554Aug 12
Rodman David MalcomChief Medical OfficerAug 10 '26Sale27.092,17058,78551,384Aug 12
Warren EricChief Commercial OfficerJul 21 '26Option Exercise13.247,43898,47945,838Jul 23
Warren EricChief Commercial OfficerJul 21 '26Sale26.877,438199,88538,400Jul 23
Rodman David MalcomChief Medical OfficerJul 17 '26Option Exercise15.444166,42351,800Jul 20
Rodman David MalcomChief Medical OfficerJul 17 '26Sale26.5341611,03651,384Jul 20
Rodman David MalcomChief Medical OfficerJul 15 '26Sale26.616,349168,95551,384Jul 15
Rodman David MalcomChief Medical OfficerJul 13 '26Option Exercise7.2814,058102,36571,791Jul 15
Congleton JonChief Executive OfficerJul 13 '26Sale27.2410,700291,441603,621Jul 15
Rodman David MalcomChief Medical OfficerJul 13 '26Sale27.5814,058387,71757,733Jul 15
Rodman David MalcomChief Medical OfficerJul 09 '26Option Exercise16.002,17134,73659,904Jul 10
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.